Home

FRANK CONDELLA JR

CIK 1282199 · President & CEO · last filed 2016-08-03

FRANK CONDELLA JR is a President & CEO who has filed 22 SEC Form 4 insider transactions across 2 companies since 2009. The most recent filing, for JNP, was dated Aug 3, 2016. Across all open-market trades the lifetime net is +$386.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $529.7K across reported positions. 24 SEC filings were submitted jointly with COLUMBIA LABORATORIES INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$529.7K

Companies

2

Total Filings

22

Lifetime Open-Market Net

$386.3K

Filer Profile

Reported Address
354 EISENHOWER PARKWAY
PLAZA I - SECOND FLOOR
LIVINGSTON, NJ 07039
Related Filers
COLUMBIA LABORATORIES INC — 24 joint filings, latest 2016-08-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
JUNIPER PHARMACEUTICALS INC (JNP) Delisted President & CEO 85,784 — — $132.0K 5 2016-08-03
CBRX President & CEO 55,345 $9.57 $529.7K $254.3K 17 2015-02-19

Recent Filings

22 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2016-08-03 JUNIPER PHARMACEUTICALS INC (JNP) Delisted Grant (A) +6,064 $0 EDGAR
2016-07-06 JUNIPER PHARMACEUTICALS INC (JNP) Delisted Grant (A) — $0 EDGAR
2015-11-19 JUNIPER PHARMACEUTICALS INC (JNP) Delisted Buy (P) +5,000 $58.4K EDGAR
2015-05-12 JUNIPER PHARMACEUTICALS INC (JNP) Delisted Exer (M) +9,375 $46.4K EDGAR
2015-05-11 JUNIPER PHARMACEUTICALS INC (JNP) Delisted Buy (P) +10,000 $73.6K EDGAR
2015-02-19 CBRX Grant (A) — $0 EDGAR
2014-08-14 CBRX Buy (P) +10,000 $59.8K EDGAR
2014-03-12 CBRX Grant (A) — $0 EDGAR
2013-11-26 CBRX Buy (P) +5,000 $31.6K EDGAR
2013-05-15 CBRX Buy (P) +80,000 $50.7K EDGAR
Showing 1–10 of 22
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.